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ohe purpose of this fifth and final yearly review of cardio-
ascular surgery by this author remains to highlight articles
hat provide new and accurate information that should
uide management decisions for patients with cardiovascu-
ar disease. In the past, preference has been given to review
f reports that link outcomes of patients to decisions about
hether an operation should be done. The large body of
ew evidence about how an operation should be done was
onsidered more appropriate for discussions among cardiac
urgeons. However, patients increasingly include questions
f how an operation should be done when deliberating
bout whether they will consent to a proposed operation.
his patient interest in decisions about operative conduct
ow makes topics of how an operation should be performed
f broad interest to all cardiovascular specialists. The first 8
f the references in this review focus on questions about how
he coronary artery bypass grafting (CABG) operation
hould be conducted to optimize outcomes for individual
atients.
urgery for Coronary Artery Disease (CAD)
n and off cardiopulmonary bypass (pump) CABG
omparison. The Octopus study conducted at 3 centers in
he Netherlands between 1998 and 2000 randomized 281
ow-risk patients to receive on-pump CABG (n  139) or
ff-pump CABG (n  142) (1). A battery of 10 standard-
zed and validated neuropsychological tests were adminis-
ered by a psychologist blinded to treatment 1 day before, at
months, 12 months, and 5 years after operation. A
ardiovascular event defined as all-cause mortality, stroke,
yocardial infarction, or coronary intervention occurred in
0 (21.1%) of off-pump and 25 (18.0%) of on-pump CABG
Fig. 1). The primary outcome defined as cognitive outcome
t 5 years could be determined in 123 (94.5%) of 130
ff-pump patients and 117 (90%) on-pump patients. No
ifference was observed between the 2 groups in cognitive
ecline, angina status, or quality of life.
To assess cardiopulmonary bypass as a cause of cognitive
ecline, cognitive performance at baseline and 3 years was
rom the Department of Surgery/Duke Clinical Research Institute, Duke University
edical Center, Durham, North Carolina. Dr. Jones is the principal investigator of
he National Institutes of Health sponsored STICH (Surgical Treatment for Ischemick
eart Failure) trial.
Manuscript received January 14, 2008, accepted March 12, 2008.ompared in on-pump CABG patients (n 152), off-pump
urgery patients (n  75), patients with CAD but no
urgery (n  99), and subjects without CAD risk factors (n
69) (2). Neuropsychological performance was assessed by
tandardized tests of attention, language, verbal and visual
emory, visuospatial, executive function, and psychomotor
nd motor speed. No group differed significantly in any
ognitive domain in comparisons of baseline to 36-month
erformance. There were no significant differences in the
egree of change between on- and off-pump surgery. This
tudy suggests that cardiopulmonary bypass is not an im-
ortant cause of cognitive decline.
Outcomes of 13,889 off-pump CABG and 35,941 on-
ump CABG patients operated between 2001 and 2004
ere compared using data prospectively entered into New
ork State databases (3). Conversion from off- to on-pump
ABG was necessary in 226 patients whose operative
ortality was 9.7% compared with 2.45% for the total
n-pump cohort and 2.30% for the total off-pump cohort.
utcomes of these patients were included in the off-pump
ohort. Off-pump patients had less strokes (3.7% vs. 4.2%,
 0.005) but more unplanned reoperations (1.2% vs.
.8%, p  0.047) compared with on-pump CABG patients
sing risk-adjusted data. Three-year survival was 90.1% for
n-pump and 89.4% for off-pump patients (p  0.2) (Fig.
). Freedom from subsequent revascularization at 3 years
as 93.6% for on-pump and 89.9% for off-pump CABG at
years (p 0.0001) (Fig. 3). Moreover, these outcomes did
ot change in a subanalysis using 3,074 matched pairs
erved by surgeons performing at least 50% of their CABG
perations by the operative technique their patients repre-
ented in the comparison.
The current weight of evidence suggests that off-pump
ABG may offer less perioperative morbidity but at the
rice of a less effective long-term revascularization. How-
ver, differences in carefully done randomized and observa-
ional studies are sufficiently small that broad generaliza-
ions for patient groups become meaningless. Specific
aseline characteristics of individual patients will guide
election of the preferable approach for each patient as
uture data refines criteria for decisions that optimize
utcomes for the total CABG cohort treated at each center.
he New York State ratio of 2.6:1 on- to off-pump CABG
peration appears reasonable with the current state of
nowledge.
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Year in Cardiovascular Surgery April 29, 2008:1707–18ABG With or Without Mitral Valve Surgery
rospectively acquired clinical and echocardiographic data
n separate databases were merged to identify 390 patients
ho had severe (3 or 4) functional ischemic mitral
egurgitation on initial admission during which a CABG
as performed with (n 290) or without (n 100) a mitral
alve annuloplasty (4). In both unadjusted comparisons and
4 propensity-matched patient pairs, survival was similar
ver 10 years in CABG patients with or without mitral valve
nnuloplasty (Fig. 4). These well-analyzed data should
Figure 1 Proportion of Patients With a Cardiovascular Event
Cardiovascular events defined as mortality, stroke, myocardial infarction, or
repeat coronary revascularization did not differ between off-pump and on-pump
coronary artery bypass grafting (CABG) patients. Reprinted, with permission,
from van Dijk et al. (1).
Figure 2 Three-Year Kaplan-Meier Curves for Survival for Off-Pu
Numbers in the figure are survival rates and 95% confidence intervals. Numbers o
bypass at 1, 2, and 3 years, respectively, and 8,893, 6,063, and 3,155 for on-puncrease uncertainty among cardiovascular specialists about
he need for adding mitral surgery to CABG even in the
resence of severe mitral regurgitation. An accompanying
ditorial suggests the best source of a definitive answer to
his question would be an observational study using some
arge existing database of CABG operations combined with
ntraoperative telephone notification by the operating sur-
eon of intent to proceed or not proceed to open the left
trium for a mitral valve repair (5).
ingle to Multiple Arterial Conduit Comparison
wenty-year follow-up has been reported on 867 (81%) of
he 1,067 consecutive CABG operations performed by 2
ardiac surgeons from 1984 to 1987 (6). During this
nterval, multivessel CAD was treated with CABG using
ultiple arterial conduits in 71% of patients by one surgeon
nd in 26% of patients operated by the other surgeon.
ollow-up data were analyzed by treatment received and not
y surgeon. The propensity score for operation received was
ot significant in the Cox model for the end point of death.
n the overall group, 71% of patients were dead at 20 years
nd 52% of these died of cardiac causes. The composite of
ortality, myocardial infarction, percutaneous coronary
ntervention (PCI), and redo CABG was reduced by
ultiple compared with single internal mammary artery
se (p  0.013).
edication Use in CABG Patients
he risks of 3 hemorrhage-sparing medications commonly
sed in cardiac surgery were evaluated in a 2-phase obser-
ational study (7). Between November 11, 1996, and June
0, 2000, 69 clinical sites enrolled 4,374 CABG patients (18
atients/site) and collected 7,500 fields of baseline and
nd On-Pump Bypass Surgery (Matched Cases)
nts at risk were 8,867, 6,027, and 3,188 for off-pump coronary artery
ronary artery bypass grafting. Reprinted, with permission, from Hannan et al. (3).mp a
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April 29, 2008:1707–18 Year in Cardiovascular Surgeryn-hospital data on each patient. Protocol permitted care
roviders to make decisions for use of hemorrhage-sparing
edication. Aprotinin was used in 1,295 (29.6%); aminoca-
roic acid was used in 883 (20.2%); tranexamic acid was
sed in 822 (18.8%); and no hemorrhage-sparing medica-
ion was used in 1,374 (31.4%) of the 4,374 patients. At
lose of the in-hospital phase on June 30, 2000, a 4-year
rogram of data collection was begun by 62 of the 69 sites.
he 7 centers that did not participate in the follow-up phase
ad enrolled 498 patients (71 patients/site). Cox regression
nalysis was performed on all of the 4,374 patients enrolled
n the in-hospital phase with the data of surgery as time 0.
atients completing the in-hospital phase but not partici-
ating in the follow-up phase were right-censored at the last
ollow-up time. Multivariable logistic regression with pro-
ensity adjustment showed the 87 excess deaths during 5
ears of follow-up in the aprotinin-treated group to be
ignificant (p  0.008), whereas the 26 excess deaths in the
minocaproic acid-treated group and the 8 excess deaths in
he tranexamic acid-treated groups were not significant.
The major controversy surrounding these findings focuses
n possible confounding from an aprotinin administration
ecision that itself marks patients who are either more prone
o bleed or perceived as less able to withstand the added
isks of excessive bleeding should it occur. This concern is
easonable in that aprotinin is the most costly and the most
otent of the hemorrhage-sparing agents. Moreover, its use
as been associated with excessive intravascular thrombosis
n the past. Many experienced cardiac surgeons rarely use
ny hemorrhage-sparing medication, and few use aprotinin
outinely for CABG operations. Centers recruited to par-
icipate in this study were requested to enroll only 2% of
Figure 3 Three-Year Kaplan-Meier Curves for Freedom From Su
Revascularization for Off-Pump and On-Pump Bypass S
Numbers in the figure are rates of freedom from subsequent revascularization and
2,880 for OPCAB at 1, 2, and 3 years, respectively, and 8,624, 5,742, and 2,938
et al. (3).heir expected CABG population. Therefore, the distribu- lion of drug use in this study cannot be considered repre-
entative of medication use in the broad CABG population.
A well-conducted meta-analysis compared 8 clinical out-
omes of risk and benefit of aprotinin, aminocaproic acid,
nd tranexamic acid with placebo using data from 138
andomized controlled trials conducted in cardiac surgical
atients (8). All agents significantly reduced blood loss by
26 to 348 ml and decreased the proportion of patients
ransfused. No agent had significant differences in mortality,
troke, myocardial infarction, or renal failure. However,
protinin at high dose significantly increased the risk of
enal dysfunction but also demonstrated significantly less
otal blood loss than aminocaproic acid (184 ml) and
ranexamic acid (195 ml). These data provide a more
alanced view of the risks and benefits of hemorrhage-
paring drug use in cardiac surgical patients than the
reviously described observational study.
In the PREVENT (PRoject of Ex-Vivo vein graft
Ngineering via Transfection) IV trial, patients free of
eath or myocardial infarction at 30 days were assessed for
edication use after hospital discharge and 1 year and 2
ears after CABG (9). Individual patients were categorized
s with or without an ideal indication for antiplatelet agents,
eta-blockers, angiotensin-converting enzyme inhibitor or
ngiotensin receptor blockers, and lipid-lowering drugs.
riteria of one-half or fewer, more than one-half but not all,
nd all indicated medications separated groups of 488
16.4%), 558 (18.8%), and 1,924 (64.8%) of the 2,970-
atient cohort for evaluation of the influence of the quality
f secondary prevention medication use on death or myo-
ardial infarction at 2 years. A Cox proportional hazards
odel adjusting for baseline clinical characteristics and
ropensity for taking all medications showed a significantly
ent
ry (Matched Cases)
confidence intervals. Numbers of patients at risk were 8,466, 5,599, and
-pump coronary artery bypass grafting. Reprinted, with permission, from Hannanbsequ
urge
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Year in Cardiovascular Surgery April 29, 2008:1707–18ll medications than patients taking one-half or fewer of
ndicated medications (Table 1).
arly Discharge After CABG
he effect of early discharge after CABG on death, read-
ission, and costs was examined on 55,889 New York
ABG patients discharged home from 1995 to 1998 (10).
arly discharge was defined as a post-operative stay below
he 15th percentile for patients with similar risk. Using this
efinition based on individual patient risk, 17% of patients
ere discharged early. This approach normalized outcomes
o minimize the tendency of healthier patients at baseline to
ave less post-operative complications and shorter hospital
tays than the total population. The primary clinical out-
Figure 4 Survival After CABG Either Alone or With Concomitant
MV Annuloplasty for Functional Ischemic MR
Symbols represent deaths positioned according to the Kaplan-Meier estimator,
vertical bars are 68% confidence limits, and numbers in parentheses are
patients still alive. Solid lines are parametric estimates enclosed within 68%
confidence limits. (A) Unadjusted survival, based on 37 deaths after coronary
artery bypass grafting (CABG) alone and 92 after CABG  mitral valve (MV)
annuloplasty. (B) Propensity-matched survival, based on 19 deaths after CABG
alone and 19 after CABG  MV annuloplasty. MR  mitral regurgitation.
Reprinted, with permission, from Mihaljevic et al. (4).ome of all-cause death (1%) or readmission (19%) within y0 days of discharge after CABG occurred in 20% of
atients. About four-fifths of readmissions appeared related
o CABG, including infection (20%), heart failure (14%),
schemic events (9%), respiratory illness (7%), arrhythmia
7%), pulmonary embolism or deep vein thrombosis (6%),
troke (4%), and gastrointestinal disorders (2%).
Patients discharged early were less likely to die or be
eadmitted within 60 days of discharge (15%) than patients
ith typical (20%) or late discharges (26%). Death rates
ere 0.44 for early discharge, 0.69 for typical discharge, and
.71 for late discharge. The percentage of early discharge
fter CABG among the 32 New York hospitals ranged from
% to 42%. After adjusting for patient risk, the odds ratio
or death or readmission within 60 days ranged from 0.7 to
.4 (p  0.001). No association was demonstrated between
hospital’s tendency to discharge early and its risk-adjusted
n-hospital mortality rate.
In the Medicare subset of this population for whom cost
ata could be obtained, lower costs of $1,755 within 60 days
fter early discharge combined with an average savings of
4,554 for the CABG hospitalization resulted in a $6,309
verage cumulative savings for patients discharged early
elative to those with typical discharges.
These data clearly document that from 1995 to 1998
ore patients undergoing CABG in New York State could
ave safely been discharged home sooner. Now, almost a
ecade later, early discharge has become more widely
ccepted as standard practice. Increasingly, the potential
edical liability for occurrence of an untoward event soon
fter discharge is becoming a more dominant concern for
ardiac surgeons. Application of methodology used in this
eport to more modern datasets would better inform optimal
iming of discharge decisions and permit patients to leave
he hospital for the comfort of home as soon as risk was
quivalent in both environments.
omparison of CABG and Percutaneous
ransluminal Coronary Angioplasty (PTCA)
he BARI (Bypass Angioplasty Revascularization Inves-
igation) trial. The 10-year final follow-up of the BARI
rial conducted in 1,829 patients showed that 242 (26.5%)
f 914 CABG patients died compared with 265 (29%) of
15 PTCA patients (11) (Fig. 5). The statistically insignif-
cant survival advantage of 2.5% for CABG over PTCA
dded an average of 84 days of survival over the average
ollow-up of 10.4 years. After further follow-up, the earlier
eported survival advantage for CABG over PTCA in the
ubset of patients with diabetes no longer had statistical
alidity. Over the 10-year follow-up, the PTCA cohort
nderwent 3.6-fold more subsequent revascularizations than
he CABG cohort.
Therefore, the most honest way to communicate BARI
esults to a patient considering PCI today would be, “If you
re among the one-third of patients most suitable for PCI,
ou may pursue a strategy of PCI to treat your CAD
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April 29, 2008:1707–18 Year in Cardiovascular Surgeryithout risk of excess death as long as you accept a
ikelihood of more subsequent procedures.”
ost effectiveness comparison. An evidence synthesis ap-
roach to cost effectiveness analysis compared PCI stenting
ith minimally invasive CABG with an internal thoracic
rtery graft to the left anterior descending coronary artery
12). A meta-analysis of randomized trials comparing the 2
trategies was performed using Cochrane Collaboration
ethodology. Costs were based on the British National
ealth Service cost report. A base care analysis for a
1-year-old man was calculated for a 10-year interval in
-year Markov simulation cycles.
Over 10 years, coronary stenting cost £6,317 and pro-
ided 6.72 quality-adjusted life years compared with a cost
f £7,146 that provided 6.85 quality-adjusted life years for
ABG. This minimal incremental cost effectiveness equates
o a cost effectiveness ratio of £6,274 per quality-adjusted
ife year. Sufficiently small differences demonstrated in this
nalysis justified the conclusion that cost does not need to be
onsidered in clinical decisions made between these 2
evascularization strategies.
Figure 5 Overall Survival and Survival Free of
Q-Wave MI by Randomized Treatment
The blue solid lines indicate coronary artery bypass grafting (CABG), and percu-
taneous transluminal coronary balloon angioplasty (PTCA) is indicated by red
dashed lines. MI  myocardial infarction. Reprinted, with permission, from the
BARI Investigators (11).
ssociation Between Composite Medication Use and Death or MI a
Table 1 Association Between Composite Medication Use and D
Comparison Group on Basis of
Composite Medication Use Number of Patients 2-Year Dea
Patients taking one-half or fewer of the
indicated medications
488 8.
Patients taking more than one-half but
not all of the indicated medications
558 5.
Patients taking all indicated medications 1,924 4.
Adjusted for age, gender, recent myocardial infarction (MI) (within 30 days before coronary artery b
o be taking all medications, and the number of indicated medications for each patient. Reprintepardiac Surgery for Advanced Heart Failure
entricular assist devices (VADs). A decade of use of
AD implantation for management of shock after cardiac
urgery was reviewed using clinical data from the Society of
horacic Surgeons’ National Cardiac Database (13). Be-
ween January 1995 and December 2004, 5,735 VADs were
mplanted in 601 centers. Ventricular assist device implan-
ation occurred in 0.3% of the cardiac operations reported
uring the decade. Patients who underwent cardiac trans-
lantation during the same hospitalization were excluded to
ocus analysis on VAD use for failure to wean from
ardiopulmonary bypass.
The primary end point, defined as in-hospital death or
eath within 30 days of hospitalization for cardiac surgery,
ccurred in 45.9% of patients. Logistic regression identified
aseline characteristics known to relate strongly to operative
ortality to also predict mortality with VAD use. Baseline
haracteristics with an odds ratio 2.0 included salvage
rocedure, reoperation, and dialysis. Age and diabetes were
ot predictive, and mortality was 56.3% in the 240 patients
ounger than 40 years and 29.6% in the 311 patients older
han 79 years. This observation emphasizes the difficulty in
etermining the true denominator of those eligible for a
igh-risk procedure to treat a high-mortality condition.
learly, the patient group younger than 40 years was more
ggressively treated for more hopeless-appearing conditions
han the octogenarians who were most likely to be the most
alvageable of those in their age group. Fortunately, collec-
ion of more detailed information about reasons for VAD
mplantation began in 2004, so future reports will better
nform the appropriate use of VADs in patients who remain
n critical condition at the conclusion of a cardiac operation.
A prospective observational study conducted at 7 major
.S. centers enrolled 67 patients who received a left
entricular assist device (LVAD) as a bridge to transplan-
ation and survived at least 30 days between August 2001
nd October 2003 (14). The 37 nonischemic and 30
schemic class IV heart failure patients had a left ventricular
jection fraction (LVEF) of 0.17  0.7. On day 30, the
VEF had increased to 0.34  0.12 but by 120 days had
ecreased to values observed before LVAD insertion. De-
isions to explant LVADs for recovery were individualized
t each center. At 134  108 days, 11 (15%) of the 67
ears
or MI at 2 Years
Rate Adjusted Hazard Ratio* 95% Confidence Interval p Value
1.69 1.12–2.55 0.013
1.20 0.71–2.04 0.493
Reference Reference Reference
rafting), congestive heart failure, creatinine clearance, history of diabetes mellitus, the propensity
permission, from Goyal et al. (9).t 2 Y
eath
th/MI
0%
0%
2%atients remained on support devices, 44 (66%) had received
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Year in Cardiovascular Surgery April 29, 2008:1707–18ransplantation, and 6 (9%) had died. Device explantation
or recovery was done in 6 (9%) of patients. All 6 patients
emained clinically stable at 6 months. The LVEF remained
table in 4 of these patients.
Between November 2002 and December 2005, data were
rospectively entered into a Food and Drug Administra-
ion–mandated registry on all patients who underwent
eartMate LVAD (Thoratec Corp., Pleasanton, Califor-
ia) insertion at 66 U.S. hospitals. Data from 280 (91%) of
he 309 total patients who gave consent were analyzed to
dentify predictors of in-hospital mortality (15). The mean
ge was 60.7  12 years, and 65% of patients had ischemic
eart failure. The mean LVEF was 0.176  0.006. Survival
stimates were 86.1% at 30 days, 56.0% at 1 year, and 30.9%
t 2 years after censoring patients who died (n  155) or
ere transplanted (n  47). A total of 155 (55%) of 280
atients died during a mean support time of 10.4 months
range 1 day to 3.6 years). In-hospital deaths occurred in 76
64.4%) of 118 deaths within a year of implantation.
A risk score was developed for 90-day mortality using
ata from 222 patients having complete baseline data. Liver
nd renal dysfunction, low serum albumin, and hematologic
nd coagulation abnormalities were the strongest markers of
isk. The odds ratios of 9 variables found to be predictive of
0-day in-hospital mortality in multivariable modeling were
sed to create a simplified risk score (Table 2) that had a
-statistic of 0.89 in the population on which it was
erived. The score appeared to aid discrimination of low-,
edium-, high-, and very high-risk patients for the end
oints of 90-day in-hospital mortality and survival to
ospital discharge, 90 days, and 1 year (Fig. 6).
Between January 1, 1990, and January 1, 2005, 48,982
atients over the age of 18 years were listed for heart
ransplantation on the United Network of Organ Sharing
UNOS) waiting list (16). Figure 7 depicts the annual
isting of 18,004 UNOS status 1 and 30,978 UNOS status
patients and the percentage of listed patients undergo-
ng transplantation each year. Survival on waiting lists
ignificantly improved over this interval. Predictors of
eaths by Cox proportional multivariable modeling
ithin 2 months of listing included need for mechanical
entilation, failed heart transplant, status 1A intra-aortic
ultivariable Analysis of Risk Factors for 90-Day In-Hospital Morta
Table 2 Multivariable Analysis of Risk Factors for 90-Day In-Ho
Patient Characteristics Odds Ratio
Platelet count 148 103/l 7.7 (3.0–
Serum albumin 3.3 g/dl 5.7 (1.7–
International normalization ratio 1.1 5.4 (1.4–
Vasodilator therapy 5.2 (1.9–
Mean pulmonary artery pressures 25 mm Hg 4.1 (1.5–
Aspartate aminotransferase 45 U/ml 2.6 (1.0–
Hematocrit 34% 3.0 (1.1–
Blood urea nitrogen 51 U/dl 2.9 (1.1–
No intravenous inotropes 2.9 (1.1–eprinted, with permission, from Lietz et al. (15).
CI  confidence interval.alloon support, and creatinine 1.5 mg/dl for status 1
atients and restrictive cardiomyopathy and intravenous
notropes for status 2 patients. The 1-year survival of
tatus 2 candidates approaches outcomes of heart trans-
lantation, suggesting that early listing of some of these
atients might not be justified.
ardiac Surgery for Congenital Heart Disease
etween November 1, 1994 and October 3, 2005, 164
onsecutive pediatric heart transplants were performed on
54 patients with ages ranging from 20 days to 21 years with
median age of 5.2 years (17). Follow-up over 0.4 to 19.5
ears averaged 5.9  4.8 years with only 1 patient lost to
ollow-up. Overall Kaplan-Meier survival was 82.3% at 1
ear, 65.3% at 5 years, and 54.4% at 10 years. Dominant causes
f the 59 (38.3%) deaths of 164 patients were transplant CAD
n 20 (13%), post-operative multisystem organ failure in 15
9.7%), and rejection in 8 (5.2%). The probability of surviving
year was significantly less during the first half compared with
he second half of the series. However, survival after 1 year
emained constant throughout the entire experience. Cox
Figure 6 Survival After LVAD Implantation as Destination
Therapy by the Candidate’s Operative Risk
LVAD  left ventricular assist device.
Reprinted, with permission, from Lietz et al. (15).
fter LVAD as Destination Therapy (n  222)
l Mortality After LVAD as Destination Therapy (n  222)
CI) p Value Weighted Risk Score
0.001 7
0.001 5
0.01 4
0.008 4
0.009 3
0.002 2
0.02 2
0.03 2
0.03 2lity A
spita
(95%
19.4)
13.1)
21.8)
14.0)
11.2)
6.9)
7.6)
8.0)
7.7)
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April 29, 2008:1707–18 Year in Cardiovascular Surgeryroportional multivariable models showed need for endotra-
heal intubation 5 days post-operatively to be the strongest
redictor of 1- and 5-year mortality.
Late outcome could be confirmed in 96% of the 6,460
hildren in the Finnish Research Registry of Pediatric
ardiac Surgery who underwent 7,240 cardiac operations
uring 1953 to 1989 (18). Death certificates and medical
ecords were used to classify congenital heart disease–related
eaths as related to heart failure: sudden, perioperative, and
ardiovascular. Each patient’s survival was compared with
Figure 7 The Number of UNOS Status 1 and 2 Heart Transplant
The number of United Network of Organ Sharing (UNOS) status 1 candidates listed
patients in 2005. During the same time period, the number of patients listed as U
in 2005. These trends were associated with an increased proportion of the listed-
77% in 2005 (red line). Reprinted, with permission, from Lietz et al. (16).
Figure 8 Proportion of Causes of Death
Numbers in blocks define the actual number of deaths in each diagnostic group. A
patent ductus arteriosus; TGA  transposition of the great arteries; TOF  tetralo
with permission, from Nieminen et al. (18).hat in the age-, gender-, and time-matched general popu-
ation each year. On October 29, 1998, the closing date of
he study, 5,193 (80%) of the 6,460 operated patients were
nown to be alive and living in Finland. Death occurred in
,028 (16%) patients, and outcome was unknown in 239
4%) patients. Death occurred within 30 days of operation
n 836 (7%) patients and more than 30 days in 592 (9%)
atients. Figure 8 depicts the cardiac/noncardiac cause of
eath by diagnosis. A total of 397 (67%) deaths were related
nd 185 (81%) were unrelated to congenital heart disease.
didates Listed in the U.S.: Years 1990 to 2005
eart transplantation in the U.S. decreased from 836 patients in 1990 to 1,159
tatus 2 decreased from 2,332 patients listed in 1990 to 1,147 patients listed
splanted heart transplant candidates per calendar year from 41% in 1990 to
atrial septal defect; COA  coarctation of aorta; Misc  miscellaneous; PDA 
Fallot; UVH  univentricular heart; VSD  ventricular septal defect. Reprinted,Can
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Year in Cardiovascular Surgery April 29, 2008:1707–18igure 9 compares survival of the cohort to the matched
eneral population. The 45-year survival was 89% of that of
he general population. Male patients had lower survival
han female patients. Figure 10 illustrates the mode of
ardiac deaths for each diagnosis. The most common mode
f death was heart failure usually associated with pulmonary
ypertension. Common noncardiac causes of death included
eurologic disease and pneumonia usually associated with
ental retardation.
The value of aspirin after operations for complex cyanotic
ongenital heart disease was evaluated between January
001 and August 2005 at 15 centers in the U.S., France, and
ermany (19). The specific diagnoses of the 1,004 patients
Figure 9 Relative Survival (Survival of Patients/Survival
of General Population) of All Patients
Survival of general population is 100%. Dotted lines represent survival for con-
genital heart defect (CHD)-related causes. Follow-up started from the patient’s
first operation. Reprinted with permission from Nieminen et al. (18).
Figure 10 Proportion of Modes of CHD-Related Death in Differe
Perioperative indicates death within 30 days after second, third, or fourth operatio
actual number of death in each group. CHD  congenital heart defect; other abbrenrolled included hypoplastic left ventricular syndrome (n
46), tricuspid atresia (n 103), complex tetralogy of Fallot
n  127), pulmonary atresia (n  177), heterotaxy syn-
rome (n 38), and other forms of complex single ventricle
n  213). Operations performed included shunts per-
ormed without (n  344) and with (n  287) cardiopul-
onary bypass and Norwood (n  323) and Sano (n  50)
rocedures. Mean age at surgery was 8 days. Aspirin was
sed in 806 (80%) of 1,002 patients, and its use was not
ecorded in 2 of the 1,004 infants studied. Outcomes
valuated were time from initial procedure to death, shunt
hrombosis, hospitalizations for Glenn or hemi-Fontan
urgery at age 4 months, and a composite of the 3
utcomes. Table 3 summarizes these outcomes at 1 year
fter the initial operation. A Cox regression model showed
onuse of aspirin to be the strongest determinant of death at
year, and especially for patients who underwent a shunt on
ardiopulmonary bypass or a Norwood procedure (Table 4).
ow-dose aspirin (20 mg) and high-dose aspirin (40 mg)
ere associated with similar mortality rates (Fig. 11).
urgery for Cardiac Valve Disease
wo risk scores for predicting mortality of operations for
alvular heart disease were developed and validated using
ata from the New York State Cardiac Surgery Reporting
ystem (20). The same analytic strategy was used to produce
nd validate separate risk scores for isolated cardiac valve
perations and for cardiac valve operations combined with
ABG. The 2001 to 2003 datasets from patients undergo-
ng isolated cardiac valve operation (n 10,702, in-hospital
ortality 4.41%) and cardiac valve operation with CABG
n  8,823, in-hospital mortality 8.89%) were divided into
evelopment and validation cohorts. Risk factors found to
fect Groups
bers in blocks define the
s as in Figure 8. Reprinted, with permission, from Nieminen et al. (18).nt De
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April 29, 2008:1707–18 Year in Cardiovascular Surgerye significant predictors of death in the development co-
orts were confirmed to be significant in the validation
ohorts. Coefficients of these significant variables were
ormalized to integers. The total possible risk score for any
atient ranged from 0 to 49 for isolate valve patients and
rom 0 to 35 for valve with CABG patients. The accuracy of
he 2 risk scores was tested in the 1998 to 2000 datasets
rom patients undergoing isolated cardiac valve operation
n  9,662, in-hospital mortality 5.22%) and cardiac valve
peration with CABG (n  8,463, in-hospital mortality
.32%). After adjusting for mortality differences with the
001 to 2003 patients, risk scores developed from 2001 to
003 data performed with acceptable accuracy in predicting
ortality and length of stay of the 1998 to 2000 patient
ohort.
Table 5 is used to calculate the risk score for an individual
atient based on his or her clinical characteristics and the
peration to be undertaken. The mortality expected in New
ork State would be that corresponding to the individual
atient’s risk score on Table 6 if the operation is to be an
solated valve operation and on Table 7 if the operation is to
e a valve with CABG operation.
These risk scores provide a bedside estimate of the
ortality any patient would have experienced if they under-
ent operation at an average New York hospital from 2001
o 2003. These estimates can be adapted for use by any
enter by adjusting the look-up table mortalities higher or
ower by the ratio of their total mortality to the New York
otal mortality. Moreover, cardiac surgical practices can easily
eep running averages of expected to compare with observed
ortalities to monitor operative outcomes over time.
The role of valve surgery in left heart infective endocar-
itis was examined in 546 consecutive patients diagnosed
etween 1980 and 1998 (21). The primary outcome was
aplan-Meier Event Rate Estimates by Procedure
Table 3 Kaplan-Meier Event Rate Estimates by Procedure
End Point
Shunt Without
Cardiopulmonary Bypass
Shunt With
Cardiopulmonary Bypa
Shunt thrombosis 28/344, 11 (7–15) 37/287, 16 (11–21
Glenn hospitalization 19/257, 9 (5–12) 37/248, 18 (13–24
Death 37/344, 13 (9–16) 71/287, 30 (24–36
Composite 55/257, 24 (18–29) 101/248, 46 (39–53
vents are tabulated as number of patients with at least 1 event/total patients. Kaplan Meier even
ermission, from Li et al. (19).
nfluence of Aspirin Use on 1-Year Mortality of,004 Patient Surviving at Least 14 D ys Afterperation for Cyanotic C genit l Heart Disease
Table 4
Influence of Aspirin Use on 1-Year Mortality of
1,004 Patients Surviving at Least 14 Days After
Operation for Cyanotic Congenital Heart Disease
Operation Hazard Ratio (95% CI)* p Value
Shunt without cardiopulmonary bypass 0.41 (0.16–1.03) 0.057
Norwood 0.10 (0.06–0.17) 0.001
Shunt with cardiopulmonary bypass 0.34 (0.19–0.60) 0.001
Sano 0.68 (0.09–5.33) 0.714
From Cox model of adjusted outcomes in a population with 80% overall aspirin use. Adapted, with
ermission, from Li et al. (19).
CI  confidence interval.ll-cause mortality within 6 months of the diagnosis of
nfective endocarditis. To adjust for survival bias, follow-up
imes for nonsurgical patients were required to be at least as
ong as a respective propensity-matched patient. A total of
29 (23.6%) of 546 patients underwent surgery within 30
ays of diagnosis. Death occurred in 99 (23.7%) of nonsur-
ical and 35 (27.1%) of surgical patients. In the subset of
atients matched by propensity score, diagnosis decade, and
ollow-up time, 18 (19.4%) of 93 nonsurgical and 27 (29%)
f 93 surgical patients died (p  0.56). Because the
roportional hazard assumption was violated on both time-
ependent covariate analyses, a partition analysis was done
o distribute the early high risk of death within 7 days of
peration. Analysis of the total cohort with the entire risk of
he interval between diagnosis and operation assigned to the
urgical patients produced a hazard ratio of 1.9 (1.1 to 3.2)
p  0.02). However, assigning the risk of only the last 3
ays of waiting time before operation to the surgical cohort
ecreased the hazard ratio to 1.5 (0.9 to 2.6) (p  0.11).
learly, clinical deterioration caused many of these patients
o be taken to surgery in a high-risk state. Future efforts to
rovide data useful to optimize the use and timing of cardiac
urgery in these high-risk patients should define the surgical
ohort at the time informed consent documents for opera-
ion are signed.
Figure 11 Influence of ASA Dose on Survival
Freedom from death, initial procedure to 1 year of follow-up; aspirin (ASA) use
for open shunt  shunt on cardiopulmonary bypass, low ASA  20 mg, high
ASA  40 mg. Reprinted, with permission, from Li et al. (19).
Norwood Sano Any
31/323, 11 (7–14) 3/50, 8 (0–17) 99/1,004, 12 (10–15)
38/323, 15 (10–19) 4/49, 11 (1–20) 98/877, 14 (11–16)
101/323, 34 (28–39) 14/50, 37 (20–55) 223/1,004, 26 (23–29)
133/323, 43 (38–49) 17/49, 42 (26–59) 306/877, 38 (35–42)
as percents tabulated as 1 minus survival rate at 1 year 95% confidence interval. Adapted, withss
)
)
)
)
v
2
b
t
a
c
p
i
w
o
(
f
w
m
C
p
o
s
d
2
e
S
y

R
T
c lve ope
r
C
A
1716 Jones JACC Vol. 51, No. 17, 2008
Year in Cardiovascular Surgery April 29, 2008:1707–18A cohort of 4,617 adult patients who underwent aortic
alve replacement by a single surgical group from 1961 to
003 for aortic stenosis (47%), aortic insufficiency (14%), or
oth aortic stenosis and insufficiency (39%) were followed
hrough 2005 (22). Concomitant CABG was added to
ortic surgery in 34% of these patients, but none had
oncomitant replacements of other valves. As of 2005, these
atients had returned 22,396 yearly questionnaires provid-
ng follow-up for up to 41 years. The mean age at operation
as 65 (range 20 to 94) years, and 502 patients were
ctogenarians and 23 patients were nonagenarians.
Among the 4,617 aortic valve replacement patients, 2,382
51.6%) were dead and 2,235 (48.4%) were still being
isk Score for Predicting In-Hospital Death for Cardiac Valve Opera
Table 5 Risk Score for Predicting In-Hospital Death for Cardiac
Variable Criteria for Isolated Valve Operat
Operation performed Aortic valve replacement
Mitral valve replacement
Mitral valve repair
Multiple valve repair or replacemen
Age (yrs) 45
46–54
55–64
65–74
75
Gender (female)
Hemodynamic state Unstable
Shock
Pre-procedure myocardial infarction
14 days
Ejection fraction
Endocarditis
Creatinine 2.5 mg/dl
Renal failure Requiring dialysis
Previous open heart operation
Chronic obstructive pulmonary disease
Hepatic failure
Vascular disease Peripheral arterial disease
o estimate operative mortality, total all numbers that correspond to clinical characteristics of an
orrespond to the total patient risk score. Use Table 7 to determine operative mortality of cardiac va
isk score. Adapted, with permission, from Hannan et al. (20).
onversion of Isolated Cardiac Valve Operation Risk Score Into Pre
Table 6 Conversion of Isolated Cardiac Valve Operation Risk S
Risk Score Mortality (%) Risk Score
3 1.0 11
4 1.1 12
5 1.4 13
6 1.8 14
7 2.2 15
8 2.8 16
9 3.4 17
10 4.3 18dapted, with permission, from Hannan et al. (20).ollowed. The complete lifetimes of the living patient cohort
ere simulated by the Gompertz parametric regression
odel using age, gender, valve position, and concomitant
ABG data from the entire patient group. For the 2,382
atients who died, a total of 17,525 follow-up years were
bserved (7.4 years mean follow-up). For the 2,235 cen-
ored alive patients, a total of 14,146 follow-up years were
ocumented (6.3 years mean follow-up) and an additional
1,652 years of follow-up were imputed using the Gomp-
rtz regression model (9.7 years of imputed follow-up).
urvival by decade after operation was 50  0.9% at 10
ears, 20 1.0% at 20 years, 6.8 0.8% at 30 years, and 3.9
0.8% at 40 years (Fig. 12). Based on reasonable assump-
e Operations
Score Criteria for Valve With CABG Operation Score
0 Aortic valve replacement/CABG 0
2 Mitral valve replacement/CABG 3
0 Mitral valve repair/CABG 2
5 Multiple valve repair or replacement/CABG 4
0 60 0
1 61–69 1
3 70–79 3
5 80 5
7
2 2
6 Unstable 2
7 Shock 5
24 h 3
3 1–7 days 2
0 0.20 3
0.20–0.29 2
0.30–0.39 1
4 3
4 Creatinine 2.5 mg/dl 3
6 Requiring dialysis 4
3 2
2 0
7 0
Cerebrovascular disease 1
Extensively calcified ascending aorta 2
3 Diabetes 1
al patient. Use Table 6 to determine operative mortality of isolated cardiac valve operations that
rations combined with coronary artery bypass grafting (CABG) that correspond to the total patient
d In-Hospital Mortality
Into Predicted In-Hospital Mortality
Mortality (%) Risk Score Mortality (%)
5.3 19 26.2
6.6 20 30.9
8.2 21 36.0
10.1 22 41.5
12.4 23 47.1
15.1 24 52.9
18.3 25 58.5
22.0 26 64.0tions
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April 29, 2008:1707–18 Year in Cardiovascular Surgeryions, the cost effectiveness ratio to aortic valve replacement
as $13,528 per quality-adjusted life year and increased
ith age up to $19,826 for octogenarians and to $27,182 for
onagenarians.
A double-blind trial conducted at 3 Finnish University
ospitals from August 2005 to June 2006 evaluated 100 mg
ydrocortisone and placebo for prevention of atrial fibrilla-
ion in 241 consecutive patients undergoing CABG or
ortic valve surgery without prior atrial fibrillation or flutter
23). The primary end point of a 5-min or longer episode of
trial fibrillation within the first 84 h after cardiac surgery
ccurred in 58 (47.9%) of 121 placebo and 36 (30%) of 120
ydrocortisone-treated patients (p  0.01). Whether hy-
rocortisone, which presumably acts to decrease the peri-
perative inflammatory response, or other agents such as
eta-blockers that have a more direct myocardial effect, will
rove most beneficial to reduce atrial fibrillation in cardiac
urgical patients will await further studies.
cknowledgment
he author would like to acknowledge Vanessa Moore for
er contributions in the preparation of this manuscript.
Figure 12 Influence of Aortic Valve Replacement on Survival
Survival of patients with severe, unoperated aortic valve disease from the liter-
ature (Wu et al. [22] references 7 to 9) and survival of 4,617 patients after
aortic valve replacement from the authors’ series (thick black curve).
Reprinted, with permission, from Wu et al. (22).
onversion of Cardiac Valve Operation With CABG Risk Score Into
Table 7 Conversion of Cardiac Valve Operation With CABG Risk
Risk Score Mortality (%) Risk Score
0 1.18 8
1 1.6 9
2 2.0 10
3 2.7 11
4 3.5 12
5 4.6 13
6 5.9 14
7 7.7 15
dapted, with permission, from Hannan et al. (20).
CABG  coronary artery bypass grafting.eprint requests and correspondence: Dr. Robert H. Jones,
uke Clinical Research Institute, P. O. Box 17969, Durham,
orth Carolina 27715. E-mail: jones060@mc.duke.edu.
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APPENDIX
or the status of major ongoing randomized clinical trials
n cardiac surgical patients, please see the online version of this article.
